Listing is not for cash, because the long-term battle of medical e-commerce has just begun.
The stock market in August was as hot as the weather. In addition to the sharp fall in A-shares, Chinese stocks in Hong Kong stocks also fell sharply, including the most famous unicorn companies such as BAT and Xiaomi. Shares of previously sought after biopharmaceutical companies also fell sharply, but this did not stop more similar companies from going to IPOs, such as the latest one called 1 drug network. 1Pharmaceutical Network is a company with a core business of pharmaceutical e-commerce. Its financial data is not beautiful. In 2017, its revenue was 960 million, but its loss was 250 million. In the first half of 2018, its income was 730 million and its loss was 1.3. Billion. It seems that the business is growing rapidly. In fact, the growth in 2018 is mainly from the B2B wholesale business, which has a large amount of gross profit but the gross profit is very small. The traditional B2C retail business has a weak growth. According to the previous disclosure of 1 drug network, since the establishment in 2010, the financing has exceeded 1.8 billion yuan. The company's existing cash and short-term investment is about 690 million, and at least 1.1 billion is lost. Because the pharmaceutical e-commerce business is still in the stage of staking, it is difficult for the company to achieve profitability within 2-3 years. Under the circumstance that the overseas investors' valuation of the Chinese stocks is not high, the stock price after the 1st online market may be under great pressure, and it is difficult for shareholders to withdraw. For example, Ping An’s doctor, who has a similar business but a larger scale, broke the first day of listing, and the IPO has fallen by 30% in the past four months. Since the listing can not be cashed out, why should the 1 drug network be listed on the market when the market is not good? And it is said that there are still many pharmaceutical e-commerce companies ready to go public or spin off. The direct reason may be that for the winter, the existing assets of 1 drug network can only support more than 2 years at a loss rate of more than 200 million per year. Although the company is listed as the first group of pharmaceutical e-commerce, it has not found a clear profit direction, and has not distanced away from competitors. Considering the overall economic slowdown, startups have already predicted that financing will be more difficult in the future, so it is necessary to reserve enough funds to prepare for the unexpected. Take Ping An Good Doctor as an example. Although the stock price is sluggish, the company's cash equivalents are as much as 5.5 billion, which can support 6 years at current loss rate. Qiang is very appreciative of this cautious approach of “deep digging holes and accumulating food.†China’s first online pharmacy was introduced in 1998, but medical e-commerce is still in its infancy, which may be contrary to many people’s intuition. . Although China has the world's first e-commerce penetration rate, pharmaceutical products are also very suitable for e-commerce channels, but the following factors limit the development of pharmaceutical e-commerce: The lag in the development of Internet medical care has made medical e-commerce companies lack application scenarios and can only obtain customers by purchasing expensive traffic; Public hospitals and medical insurance funds are the main medical services and payment systems, which make the convenience and affordability of online drug purchases insufficient to attract users; The medical e-commerce company has been unable to lift the ban. From the opening of the legend 4-5 years ago to the tightening of last year, the policy of medical e-commerce has always been uncertain; The low frequency and low transmission of the purchased drugs make the repurchase rate of the medical e-commerce low and it is difficult to form a buying habit. Despite this, the Internet is still stubbornly infiltrated into all aspects of pharmaceutical circulation, and mainstream models such as B2B, O2O and B2C have ran out of a number of powerful companies. After the first two years of stagnation, under the government's vigorous promotion of telemedicine and Internet hospitals, the separation of medicines and the outflow of hospital prescriptions have become the growth engines of pharmaceutical e-commerce. However, due to the impact of China's economic environment, there have been some new policy trends recently that are bad for medical e-commerce. Therefore, everyone needs to be cautious rather than rushing. For example, the recently introduced national drug collection and collection policy has produced 70% of the hospital sales of 11 major varieties in the city. Because the mandatory hospitals complete the drug use, this will inevitably reduce the chance of prescription outflow; new drugs such as oncology drugs will be connected quickly. After the price cut, medical insurance will not only affect the sales margin but also inhibit the prescription outflow. In addition, the FDA will change the blood in the past few days, which will also strengthen the safety and supervision of medication. The point of view will rise again. Medicine is a special and regulated commodity. The speed of development of pharmaceutical e-commerce does not depend on capital or technology, but on policy factors such as prescription outflow, medical insurance docking and Internet medical development. From the current trend, this process is undoubtedly a long one, and there is no opportunity to quickly grow up by burning money. The current mainstream mode of medical e-commerce is still driven by online traffic. E-commerce is only a commodity display, trading and logistics platform. Pharmaceutical e-commerce mainly makes money by selling health care products and family planning supplies. The taste of drugs is rather weak. This kind of flow-driven medical e-commerce is already a red sea. The opportunities are mainly in the number of SKUs, traffic sources, transaction costs, etc. Tmall, Jingdong even fights a lot, rather than pharmaceutical-born startups including chain pharmacies and medicines. Commercial e-commerce. The professional background of medical e-commerce opportunities comes from in-depth services with online and offline, especially the repurchase of patients with long-term medication. The main function on the line is to create drug purchase scenarios, such as online consultation, family doctor service and chronic disease follow-up; offline is mainly for docking hospital prescription outflows and medical insurance payments, but also provides offline medical services and sales staff to visit doctors. . Take Ping An's doctor business as an example. Although its online medical service only accounts for 10% of total revenue, it is the basis of its large-scale health mall business. Because online medical care plays the role of being a guest and a guest, the Health Mall is just a realizing role. Some people think that opportunities in some segments of the pharmaceutical e-commerce, such as B2B e-commerce to rob the wholesale business of single pharmacies, small clinics and private small hospitals. The profit margin of these businesses is as thin as paper, and the logistics and financial costs are not low. They can only be regarded as “niche markets†that big pharmaceutical businesses cannot see. With the nationwide promotion of imitation consistency evaluation, pharmaceutical manufacturers tend to reduce and concentrate, and there are not many opportunities for B2B e-commerce. On the contrary, there is more demand for O2O e-commerce, which is quickly sold as a selling point, and users are relatively insensitive to price. However, this market is ultimately owned by companies such as Meituan and Hungry. Like all Internet medical and medical e-commerce companies, Ping An's online medical services are generally too thin and light, and they have not been cut into the clinic too deeply. Rich companies such as Ping An Doctors need to spend a lot of money to raise more than 1,000 full-time doctors to provide services, while other companies rely on thousands to tens of thousands of part-time doctors to provide services in fragmented time, either the operating costs are too high or the medical value is not large. . Only the increase in the cost of treatment under the same line will force the patient to make an online consultation or the medical AI evolves to an independent level of practice. The above two short-term can not be achieved, so the professional background of medical e-commerce should be ready to fight a long-term battle, and getting enough money is one of the keys to preparation.
Orthopedic external fixation system
The screw orthopedic is inserted into the bone near the fracture, and the fracture is fixed with an external fixator assembled by a chuck and a nail rod.
Indications
open fracture, nonunion, closed fracture with extensive soft tissue injury, fracture with multiple trauma, osteotomy and correction.
The use of orthopaedic external fixators is currently a superior fracture fixation technique, filling the gap between cast and internal fixation. At the same time, orthopedic external fixator has the characteristics of simple fixation method, stable, reliable and effective, and does not limit the joint movement, can be early ambulation advantages. It can reduce the time for the operator and is more friendly to the user. The external fixator was used together with the bone traction needle. In terms of the classification of orthopedic external fixators, it is mainly divided into four types: orthofix type external fixation, ilizarov type external fixation, ao synthes type external fixation,combined external fixator and common external fixators.
The external fixators in orthopaedics was used for reduction (shortening and overlapping displacement were corrected first, then lateral and angular displacement were corrected, and finally rotational and separation displacement were corrected; If closed reduction is difficult, open reduction can be considered, but the separation of soft tissue and peeling of periosteum should be minimized.
The selection of the insertion site.According to the anatomical characteristics of the soft tissue at the insertion plane, the important nerves, vessels and tendons should be avoided; The ideal entry point is the part of the bone close to the subcutaneous, in a word, generally choose the skin and bone between the muscle soft tissue is the weakest point into the needle. The installation shall facilitate observation and control of soft tissue damage, and permit any surgery that may be required, such as repair and reconstruction, dressing change, skin grafting, or bone grafting." According to the location of the bone, different diameters of the threaded needle were selected. Removal was performed after completion of late treatment.
Orthopedic External Fixator,Orthopedic Fixator,External Fixation,External Fixator Jiangsu Aomed Ortho Medical Technology Co.,Ltd , https://www.aomedortho.com